News about our portfolio and KREAXI

Amolyt Pharma Announces Appointment of Two Directors

Amolyt Pharma, a global company specializingin developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the company has made two appointments to its Board of Directors following its Annual General Meeting, which was held on June...

Amolyt Pharma announces research collaboration with PeptiDream

Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly, a rare endocrine disorder. Complete press release Amolyt Pharma